… Most of these cancer drugs are monoclonal antibodies, such as Rituxan, Avastin and
Herceptin, which justifies the industry current trust and investment in the immunotherapy and …

… competitors to create a biosimilar product which plays basically … and are developed through
extensive R&D and clinical trials. … rate following the Real World GDP growth rate of 2.25%. …

… fully account for the extensive positive transdedifferentiation … for bevacizumab, rituximab and
trastuzumab. Bevacizumab showed … in the next future with the use in therapy of biosimilars. …

… work in practice a real world data infrastructure integrating scientific … breast cancer patients
for the usage of Herceptin (Trastuzumab) on … or entrance of biosimilars after patent expiries. …

… PK modelling in a real-world population of cancer patients. … rituximab and siltuximab being
the most frequently collected. … patients in need of hospitalisation or intensive care unit (ICU) …

… The purpose of this study was to describe rituximab biosimilar safety in adult hematology …
of 24 biosimilar cures. Among adults, three infusion-related reactions of biosimilar occurred : a …

… Continued safety monitoring in real world settings, where … For example, a product could be
monitored intensively in one … prescription medicines, except biosimilar medicines and generic …

… biosimilar competition, the sales for the ever-blockbuster medicines: Avastin, Herceptin and
MabThera/Rituxan… industry because each company requires extensive costs associated with …

… to make best use of biosimilar medicines, and even generics. … Overall, during the 4 years,
Portugal was the country that … example of trastuzumab. Health Policy 2013, 113(3):313-322. 11. …

… clear oncogenic role, and its high expression in cancer genes can … drivers in cancer via
numerous methods, impacting cancer progression and prognosis. For example, in gastric cancer …